Current Edition

Dupixent

On a roll, Sanofi raises Dupixent’s peak sales target to €13B-plus

Over the years, as Sanofi and Regeneron’s Dupixent racked up new indications and approached the French pharma giant’s 10 billion euro peak sales goal, analysts had started …

Continue Reading →
allergan

UK watchdog slaps AZ, Allergan, GSK, Sanofi and Brittania for marketing breaches

When UK-based AstraZeneca announced trial data in November 2020 showing its vaccine was highly effective in preventing COVID-19, a senior AZ global executive based in …

Continue Reading →
eczema

Pfizer’s Cibinqo snags FDA approval to challenge Sanofi and Regeneron’s Dupixent in eczema

Look out, Sanofi and Regeneron: Pfizer is on the scene in atopic dermatitis with another blockbuster-to-be. Friday, the FDA approved the New York drugmaker’s oral …

Continue Reading →
Amgen

For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

Continue Reading →
diabetes

Lawmakers blast pharma for ‘outrageous’ prices and ‘anticompetitive conduct’ in culmination of 3-year probe

For years, drugmakers have targeted “weaknesses” in the U.S. healthcare system to reap dividends on older meds, The House Oversight Committee said Friday. The “outrageous …

Continue Reading →
china

Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China’s latest cost squeeze

On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign …

Continue Reading →
Amgen

Amgen asks Supreme Court to take up its high-profile PCSK9 patent case against Sanofi and Regeneron

After Amgen earlier this year suffered a third consecutive loss in its high-profile PCSK9 patent feud with Sanofi and Regeneron, the company faced two choices: …

Continue Reading →
Biocon

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

It’s official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi’s blockbuster diabetes med Lantus, will roll out …

Continue Reading →
Dupixent

Sanofi and Regeneron’s Dupixent aces another test, this time in the debilitating itch condition prurigo nodularis

Sanofi and Regeneron have big ambitions for immunology superstar Dupixent—envisioning the potential for $11 billion in annual sales. In acing a test in people with …

Continue Reading →
Federal Trade Commission

Sanofi refiles $3.2B Translate Bio buyout with FTC to allow more time for review

Ever since the Federal Trade Commission (FTC) unveiled its campaign to take a closer look at biopharma’s M&A strategies, the industry’s dealmakers have been on …

Continue Reading →